Does new photosensitizer improve photodynamic therapy in advanced esophageal carcinoma?

Maier, Andrea B.; Tomaselli, Florian; Matzi, Veronika; Rehak, Peter; Pintér, H; Smolle‐Jüttner, Freyja Maria

doi:10.1002/lsm.1124

Cited by 28 publications

(36 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Meta-analysis was not possible due to heterogeneity between the trials. All trials reported morbidity results, seven reported on mortality [113][114][115][116][117][118][119] and four reported on QoL outcomes. [115][116][117][118] Only two of the studies reported resource use, both in terms of days of hospitalisation.…”

Section: Results Of Effectiveness (Palliative Intent)mentioning

confidence: 99%

“…[107][108][109][110][111][112][113][114][115][116][117][118][119] Three studies were available only as abstracts, 107,110,111 the rest were published as full papers. In a small number of trials, the presented data did not appear to entirely support the authors' conclusions; this has been indicated in the data extraction tables.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…110 Eight studies reported on palliative PDT treatments for oesophageal cancer, four RCTs 112-114,119 and four non-randomised comparative trials. [115][116][117][118] Participants in six studies were diagnosed with advanced oesophageal cancer, and overall most trials included only patients who were not eligible for resection due to anatomical restrictions, poor health or refusal. Comparators in these trials included chemotherapy, radiotherapy, neodymium-doped yttrium aluminium garnet (Nd:YAG) laser or PDT.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…116 The duration of hospital stay in the comparison of HpD and ALA (both with HBO) ranged from 4 to 6 days in both groups. 118 …”

Section: Resource Usementioning

confidence: 99%

“…118 All three studies were carried out with patients who had advanced oesophageal carcinoma. The PDT versus PDT-plus-HBO studies both used HpD at 2 mg/kg and 630-nm illumination, and in both some patients received Nd:YAG and dilatation prior to PDT.…”

Section: Pdt and Hbomentioning

confidence: 99%

See 4 more Smart Citations

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

Fayter

Corbett²,

Heirs³

et al. 2010

Health Technol Assess

126

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of project...

show abstract

Section: Results Of Effectiveness (Palliative Intent)mentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

“…116 The duration of hospital stay in the comparison of HpD and ALA (both with HBO) ranged from 4 to 6 days in both groups. 118 …”

Section: Resource Usementioning

confidence: 99%

Section: Pdt and Hbomentioning

confidence: 99%

See 3 more Smart Citations

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

Fayter

Corbett²,

Heirs³

et al. 2010

Health Technol Assess

126

View full text Add to dashboard Cite

show abstract

Photodynamic effects of anthracyclin derivatives on squamous cell carcinoma cell lines of the head and neck

et al. 2004

View full text Add to dashboard Cite

show abstract

Endoscopic Therapy for Advanced Esophageal Cancer

Canto

Endoscopic Oncology

View full text Add to dashboard Cite

BACKGROUNDEsophageal cancer is currently the ninth leading cause of cancer death in the United States, and since the 1970s, the incidence of esophageal adenocarcinoma has been rising at an alarming rate (1). The National Cancer Institutes estimates 14,250 new cases of esophageal cancer and 13,300 deaths owing to esophageal cancer in 2004. The estimated 5-yr mortality rate remains at 5-10% (1).Unfortunately, the majority of patients present with advanced disease that is not curative by surgery (2). Palliative surgery is associated with a relatively high morbidity (20-60%) and mortality (10-33%), and approximately one-third of these patients will develop anastomotic strictures or local tumor recurrence necessitating further intervention (3). Because the median survival of such patients is less than 6 mo, palliative surgery has been replaced by nonsurgical techniques, primarily chemoradiation, brachytherapy, and/or endoscopic therapy (4). This chapter summarizes the goals, safety and efficacy, and techniques for endoscopic palliation of advanced esophageal cancer, focusing primarily on techniques for treatment of malignant dysphagia but also including treatment options for esophageal fistulas and bleeding tumors. TREATMENT OF DYSPHAGIA GOALS OF PALLIATIVE ENDOSCOPIC THERAPY FOR DYSPHAGIAMalignant dysphagia is defined as difficulty swallowing owing to malignancy and usually results from a partially or completely occluded esophageal lumen. It might present as intraluminal disease, extraluminal compression, tumor encroachment on esophageal innervation, or a combination of From: Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management.

show abstract

Does new photosensitizer improve photodynamic therapy in advanced esophageal carcinoma?

Abstract: Despite the limitations of a non-randomized study, photosensitzation with Photosan seems to be more effective in PDT of advanced esophageal carcinoma compared to ALA.

Cited by 28 publications

References 22 publications

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

Photodynamic effects of anthracyclin derivatives on squamous cell carcinoma cell lines of the head and neck

Endoscopic Therapy for Advanced Esophageal Cancer

Contact Info

Product

Resources

About